Mepolizumab reduces exacerbations in COPD with type 2 …
WEB4 days ago · Adding GSK’s mepolizumab to standard inhaled treatment reduces the frequency of moderate to severe exacerbations in chronic obstructive pulmonary disease (COPD) patients with type 2 inflammation, which contributes to lung inflammation.
GSK announces positive results from phase III trial of Nucala ...
WEBSep 6, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5) in adults with chronic obstructive pulmonary disease (COPD).
FDA Approves First Drug to Treat Group of Rare Blood Disorders in ...
WEBSep 25, 2020 · Today, the U.S. Food and Drug Administration approved Nucala (mepolizumab) for adults and children aged 12 years and older with hypereosinophilic syndrome (HES) for six months or longer without...
GSK announces FDA approval for Nucala (mepolizumab) for …
WEBJul 29, 2021 · GlaxoSmithKline plc (GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Mepolizumab Significantly Reduces COPD Exacerbations
WEBSep 12, 2024 · Findings showed a statistically significant and clinically meaningful reduction in the annualized rate of moderate to severe exacerbations with mepolizumab compared with placebo among patients treated for up to 104 weeks.
Benralizumab versus Mepolizumab for Eosinophilic …
WEBFeb 23, 2024 · We conducted a multicenter, double-blind, phase 3, randomized, active-controlled noninferiority trial to evaluate the efficacy and safety of benralizumab as compared with mepolizumab.
FDA approves first drug for Eosinophilic Granulomatosis with ...
WEBThe U.S. Food and Drug Administration today expanded the approved use of Nucala (mepolizumab) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare...
GSK achieves approval for Nucala (mepolizumab) for the …
WEBGlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) as the first targeted treatment for eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome.
GSK announces phase III results published in NEJM of mepolizumab …
WEBSep 12, 2017 · Mepolizumab has been submitted for regulatory review for eosinophilic granulomatosis with polyangiitis (EPGA, also referred to as Churg-Strauss syndrome) and is being investigated for severe hypereosinophilic syndrome, …
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary …
WEBOct 26, 2017 · Mepolizumab, a humanized monoclonal antibody, reduces eosinophil counts in blood and tissues by blocking interleukin-5, a key eosinophil cytokine, through binding to eosinophil surface...
Skip to content